Real time hbv dna assay

Manufactured by Abbott

Sourced in United States

The Abbott real-time HBV DNA assay is a quantitative in vitro diagnostic test for the detection and quantification of hepatitis B virus (HBV) DNA in human plasma or serum samples. The assay utilizes real-time PCR technology to provide accurate and reliable measurements of HBV viral load.

Automatically generated - may contain errors

Lab products found in correlation

Chemiluminescent microparticle immunoassay, by Abbott (3 mentions) Cobas 8000, by Roche (1 mentions) Liaison xl murex hiv ab ag kit, by DiaSorin (1 mentions) M2000 realtime system, by Abbott (1 mentions) Cobas 6800 system, by Roche (1 mentions) Vitros 5600, by Johnson & Johnson (1 mentions) M2000 system, by Abbott (1 mentions)

4 protocols using real time hbv dna assay

HBV Serological and Viral Load Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum HBsAg and HBeAg were tested by Abbott chemiluminescent microparticle immunoassay (Abbott Diagnostic, Chicago, IL, USA), as well as HBV DNA load was measured by Abbott real-time HBV DNA assay (Abbott Molecular, IL, USA).

Li Y., Xiao Y., Li L., Song Y., Zhai X., Liu J., Duan Z., Yan L., Ding F., Liu J., Zhu L., Jiang J., Zou H., Li L., Liang C., Wang J, & Li J. (2021). The dynamic changes of HBV quasispecies diversity in infancy after immunoprophylaxis failure: a prospective cohort study. Virology Journal, 18, 236.

+ Open protocol

+ Expand

Serological and Molecular Markers of Hepatitis B Virus

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum HBsAg, HBeAg, anti-HBs, antibody to HBeAg (anti-HBe) and antibody to HBcAg (anti-HBc) were tested by Abbott chemiluminescent microparticle immunoassay (Abbott Diagnostic, Chicago, IL, USA) using Abbott i2000 system.29 (link) HBV DNA load was measured by Abbott real-time HBV DNA assay (Abbott Molecular, IL, USA) using Abbott m2000 system. Serum HBV DNA load was reported as ‘not detected’ or ‘<1.18 log IU/mL’ when its level was below the lower detection limit of 1.18 log IU/mL.29 (link) HBV genotyping was performed by a method based on nested PCR as described previously.30 (link)

Xiao Y., Sun K., Duan Z., Liu Z., Li Y., Yan L., Song Y., Zou H., Zhuang H., Wang J, & Li J. (2019). Quasispecies characteristic in “a” determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case–control study. Gut, 69(5), 933-941.

+ Open protocol

+ Expand

Viral Hepatitis and HIV Serological Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serological markers of HBV (hepatitis B surface antigen (HBsAg) and HBeAg) and hepatitis C virus (HCV), HIV and HDV (anti-HCV, HIV and HDV) infections were tested using commercial immunoassays. At the LCVH, the assays to determine HBV and HCV markers were performed on a COBAS 8000 instrument (Roche Diagnostics, Rotkreuz, Switzerland), and anti-HIV antibodies were determined with the Liaison XL murex HIV Ab/Ag kit (DiaSorin, Saluggia, Italy). At the LCTMS, all these markers were determined on a VITROS 5600 instrument (Johnson and Johnson, New Brunswick, NJ, USA). In both centers, anti-HDV antibodies were tested using the HDV Ab kit (Dia.Pro Diagnostics Bioprobes, Sesto San Giovanni, Italy).
HBV-DNA levels were quantified using the Cobas 6800 System with the cobas HBV assay (Roche Diagnostics, Mannheim, Germany) at LCVH and using the Abbott m2000 RealTime System with the Abbott RealTime HBV DNA assay (Abbott Laboratories, Des Plaines, IL, USA) at LCTMS.

Dopico E., Vila M., Tabernero D., Gregori J., Rando-Segura A., Pacín-Ruíz B., Guerrero L., Ubillos I., Martínez M.J., Costa J., Quer J., Pérez-Garreta J., González-Sánchez A., Antón A., Pumarola T., Riveiro-Barciela M., Ferrer-Costa R., Buti M., Rodríguez-Frías F, & Cortese M.F. (2024). Genotyping Hepatitis B virus by Next-Generation Sequencing: Detection of Mixed Infections and Analysis of Sequence Conservation. International Journal of Molecular Sciences, 25(10), 5481.

+ Open protocol

+ Expand

Serological and Molecular Profiling of Hepatitis B

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum HBsAg, anti-HBs, and HBeAg levels were detected using an Abbott chemiluminescent microparticle immunoassay (Abbott Diagnostic, Chicago, IL, USA) on an Abbott i2000 system [25 (link)]. The detection range of the HBsAg assay was 0.05-250 IU/mL. Patients were considered anti-HBs positive if the level ≥10 mIU/mL. The results of the HBeAg assay were determined by the ratio of the sample relative light unit (RLU) to a cut-off RLU (S/CO) for each sample. Subjects with S/CO values higher than 1.0 were considered HBeAg-positive. HBV DNA load was quantitated by Abbott real-time HBV DNA assay (Abbott Molecular, IL, USA) using an Abbott m2000 system [25 (link)]. The lower limit of detection was 1.18 log₁₀IU/mL (15 IU/mL, 51.2 copies/mL). Negative for HBV DNA was determined by assay results reported as “not detected” or “<1.18 log₁₀IU/mL”. HBV genotyping was performed using nested PCR as described previously [26 (link)].

Li Y., Liu Z., Song Y., Xiao Y., Jiang J., Li L., Zhai X., Liu J., Duan Z., Ding F., Liu J., Zhuang H., Zhu L., Jiang J., Zou H., Wang J, & Li J. (2020). Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: a large prospective cohort study. Emerging Microbes & Infections, 9(1), 1881-1891.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!